课题基金 / 基金详情

THERAPEUTIC CLEARANCE OF COMPLEMENT C5A

THERAPEUTIC CLEARANCE OF COMPLEMENT C5A
补体 C5A 的治疗清除率
批准号：
3498114
负责人：
ROBERT C THOMPSON
金额：
$4.97万
依托单位：
SYNERGEN, INC.
依托单位国家：
美国
项目类别：
财政年份：
1988
资助国家：
美国
项目状态：
已结题
起止时间：
1988-08-01 至 1989-01-31
来源：
https://reporter.nih.gov/project-details/3498114
关键词：
adult respiratory distress syndrome bioassay biotechnology chemical structure function complement inhibitors complementary DNA disease /disorder prevention /control gel electrophoresis gel filtration chromatography gene expression high performance liquid chromatography human tissue immunopharmacology immunotherapy inflammation molecular cloning protein biosynthesis protein sequence respiratory disorder chemotherapy tissue /cell culture

项目摘要

项目成果

ROBERT C THOMPSON的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The overall goal of the proposed research is to provide a specific, practical means for inactivating C5a in patients at risk of adult respiratory distress syndrome (ARDS). C5a is a key contributory, possibly necessary factor in the pathological course of ARDS. The proteins capable of inactivating C5a noted in the literature are poorly characterized. Synergen's scientists have selected one of these proteins to isolate from human tissue, then characterize its mode of action. An assay based on this biological activity will be used to purify, characterize, clone and express the protein by recombinant DNA technologies. By reducing the action of C5a in patients at risk for ARDS, we expect that the protein will provide a useful therapeutic agent for prevention or amelioration of the pathology.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
microRNA Expression Patterns in Human Psychiatric CNS Samples
microRNA Expression Patterns in Human Psychiatric CNS Samples
Cocaine Regulation of miRNAs in Rats with Differing Vulnerability to Drug Abuse
Cocaine Regulation of miRNAs in Rats with Differing Vulnerability to Drug Abuse
国内基金
海外基金
ITS-HPLC-HRMS-Bioassay多级筛选策略指导下海洋真菌中新型抗菌活性产物的发现